CreativeOne Wealth LLC Buys 677 Shares of Danaher Corporation $DHR

CreativeOne Wealth LLC increased its stake in Danaher Corporation (NYSE:DHR) by 38.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,432 shares of the conglomerate’s stock after acquiring an additional 677 shares during the period. CreativeOne Wealth LLC’s holdings in Danaher were worth $480,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in DHR. Chicago Capital LLC grew its holdings in shares of Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after acquiring an additional 1,391 shares during the period. Weitz Investment Management Inc. boosted its position in Danaher by 6.1% in the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after purchasing an additional 30,300 shares during the last quarter. UniSuper Management Pty Ltd boosted its position in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Nvwm LLC increased its position in shares of Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after purchasing an additional 1,204 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. lifted its stake in shares of Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after purchasing an additional 6,136 shares during the period. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on DHR shares. Cowen restated a “buy” rating on shares of Danaher in a research report on Wednesday, October 22nd. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Redburn Partners set a $220.00 target price on Danaher in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada set a $241.00 price target on Danaher in a report on Tuesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 3,298 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at $4,702,593. This represents a 13.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.0%

DHR opened at $226.24 on Friday. The stock has a market cap of $159.81 billion, a price-to-earnings ratio of 46.65, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The firm’s fifty day moving average is $212.20 and its 200 day moving average is $203.21. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business posted $1.71 EPS. Danaher’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.